Exagen (XGN) Common Equity (2018 - 2026)

Exagen (XGN) has reported Common Equity for 9 consecutive years, with $14.4 million the latest figure, recorded in Q1 2026.

• Common Equity for Q1 2026 came in at $14.4 million, up 125.39% year-over-year; the trailing twelve-month figure through Mar 2026 was $14.4 million (up 125.39% YoY), and the FY2025 annual result was $17.4 million, up 82.9% from the prior year.
• Common Equity was $14.4 million for Q1 2026 at Exagen, down from $17.4 million in the prior quarter.
• Over five years, Common Equity peaked at $76.2 million in Q1 2022 and troughed at $6.4 million in Q1 2025.
• Average Common Equity over 5 years is $29.0 million, with a median of $21.0 million recorded in 2025.
• Year-over-year, Common Equity sank 67.97% in 2025 and surged 125.39% in 2026.
• Over 5 years, Common Equity stood at $42.5 million in 2022, then slumped by 46.55% to $22.7 million in 2023, then plunged by 57.96% to $9.5 million in 2024, then surged by 82.9% to $17.4 million in 2025, then fell by 17.29% to $14.4 million in 2026.
• Per Business Quant data, the three most recent Common Equity figures were $14.4 million in Q1 2026, $17.4 million in Q4 2025, and $18.1 million in Q3 2025.